Department of Plastic Surgery, MD Anderson Cancer Center, Houston, TX.
Hematologic Oncology, Dana Farber Cancer Center, Brigham & Women's Hospital, Harvard Medical School, Boston, MA.
Aesthet Surg J. 2019 Jan 31;39(Suppl_1):S3-S13. doi: 10.1093/asj/sjy331.
National Comprehensive Cancer Network (NCCN) guidelines represent the consensus standard of care for diagnosis and management of the majority of known cancers. NCCN guidelines on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) have been recognized by the US Food and Drug Administration and widely advocated by national specialty societies. Consensus guidelines have helped create a treatment standardization for BIA-ALCL at all stages of disease. NCCN guidelines are evidence-based where possible and utilize expert consensus opinion to fill in gaps that may exist. NCCN undergoes annual panel review by multidisciplinary faculty members, and this article represents the most up-to-date 2019 guidelines. Recommendations focus on parameters for achieving reliable diagnosis and disease management and emphasize the critical role for complete surgical ablation. Suggestions for adjunct treatments and chemotherapy regimens are included for advanced BIA-ALCL with lymph node involvement. BIA-ALCL recurrence and management of unresectable disease, and organ metastasis are addressed. Adherence to recognized BIA-ALCL guidelines ensures patients receive the most current efficacious treatment available.
美国国家综合癌症网络（NCCN）指南代表了大多数已知癌症的诊断和治疗的共识标准。美国食品和药物管理局（FDA）认可了 NCCN 关于乳房植入物相关间变性大细胞淋巴瘤（BIA-ALCL）的指南，并得到了国家专业学会的广泛倡导。共识指南有助于在疾病的各个阶段为 BIA-ALCL 制定治疗标准化方案。NCCN 指南在可能的情况下基于证据，并利用专家共识意见来填补可能存在的空白。NCCN 每年由多学科教员进行小组审查，本文代表了最新的 2019 年指南。建议侧重于实现可靠诊断和疾病管理的参数，并强调完全手术消融的关键作用。对于涉及淋巴结的晚期 BIA-ALCL，包括辅助治疗和化疗方案的建议。还讨论了 BIA-ALCL 的复发和不可切除疾病以及器官转移的管理。遵循公认的 BIA-ALCL 指南可确保患者获得当前最有效的治疗方法。
